Rare Disease Data Trust utilizes AI-driven analytics to identify undiagnosed rare disease patients within electronic health records while ensuring compliance with privacy regulations. This platform enables healthcare providers to deliver timely diagnoses and appropriate care, while BioPharma companies gain access to targeted patient populations for their treatments.
Funding
$525K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Rare disease patients often face significant delays and misdiagnoses due to the complexity of these conditions and the limited awareness among healthcare providers. Privacy regulations can also hinder the collaboration between BioPharma companies, who possess specialized knowledge, and healthcare providers who manage patient data.
Solution
Rare Disease Data Trust leverages AI-driven analytics to identify undiagnosed rare disease patients within electronic health records (EHRs) while adhering to privacy regulations. The platform analyzes EHR data to pinpoint patients who exhibit patterns indicative of specific rare diseases, enabling healthcare providers to deliver timely and accurate diagnoses. By facilitating the identification of these patients, the platform helps BioPharma companies connect with targeted populations for their treatments and clinical trials. The system provides alerts and educational resources to physicians, empowering them to make informed clinical decisions and improve patient care.
Target Audience
The primary target audience includes BioPharma companies seeking to identify and connect with rare disease patients for research and treatment development, as well as healthcare providers aiming to improve diagnostic accuracy and provide better care for patients with rare diseases.
Features
- AI-powered analysis of electronic health records to identify potential rare disease patients.
- Secure data handling to ensure compliance with HIPAA, Stark, AKS, and other relevant regulations.
- Disease state education provided to physicians with suspected patients.
- Facilitation of connections between BioPharma companies and healthcare providers for targeted patient identification.
- Real-time alerts to providers regarding newly diagnosed patients.